Context Therapeutics Q3 net loss narrows to $9.7 mln

Context Therapeutics

05/11/2025 22:46

Overview

Context Therapeutics Q3 net loss narrows to $9.7 mln from $17.5 mln last year

Company reports cash and equivalents of $76.9 mln, sufficient to fund operations into 2027

Ongoing Phase 1 trials show encouraging antitumor activity and safety for CTIM-76 and CT-95

Outlook

Context expects to provide updated interim Phase 1a data for CTIM-76 in Q2 2026

Company anticipates initial Phase 1a data for CT-95 in mid-2026

Context plans regulatory filings for CT-202 first-in-human trial in Q2 2026

Result Drivers

R&D EXPENSES - R&D expenses decreased to $8.7 mln from $16.8 mln primarily due to lower CT-202 and CT-95 costs, contributing to narrowed net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$9.70 mln
Q3 Basic EPS
-$0.10


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Context Therapeutics Inc is $4.50, about 75.3% above its November 4 closing price of $1.11

Press Release: ID:nGNX23VTr5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)